All In Biotech

Drug Trial Radar · NCT07687784

A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia

A Multicentre, Prospective, Randomized, Active-Controlled, Open-Label, Phase III Study to Test the Non-Inferiority of Intravenous Injection of Ferric Bepectate IV Injection Compared to Ferric Carboxymaltose for Treatment of Patients With Iron Deficiency Anaemia (IDA)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,366 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,366

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jun 2028

Study completion Jul 2028

Sponsor

Lead sponsor
AFT Pharmaceuticals, Ltd.Industry
Sponsor type
Industry
Collaborators
HungaroTrial
First posted
Jul 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to see if a new intravenous iron formulation (Ferric Bepectate IV Injection) can treat adult patients with iron deficiency anemia (IDA) by increasing blood hemoglobin (Hb) as an established formulation (Ferric carboxymaltose). It will also learn about the safety of Ferric Bepectate IV Injection. The main questions it aims to answer are: * Does hemoglobin increase by the same amount 6 weeks after each treatment? * What medical problems do participants have when being treated with the drug? Researchers will compare single dose treatment plans of Ferric Bepectate to double dose treatment plans of both Ferric Bepectate and Ferric carboxymaltose. Participants and researchers will know which drug they are being provided (open-label). Participants will visit the clinic 5 times over 6 weeks for checkups, blood tests and questionaries. The first two visits will be seven days apart and include the two doses of iron treatment.

Conditions

  • Iron Deficiency Anemia (IDA)

Interventions

  • Ferric Bepectate IV InjectionDrug

    Ferric Bepectate IV Injection 50 mg iron/mL

  • Ferric Carboxymaltose Injection [Ferinject]Drug

    Ferric carboxymaltose (Ferinject®) 50 mg iron/mL in two doses 7-9 days apart

  • Ferric Carboxymaltose Injection [Injectafer®]Drug

    Ferric carboxymaltose (Injectafer®) 50 mg iron/mL in two doses 7-9 days apart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in hemoglobin comparing one dose Ferric bepectate and two dose Injectafer treatmentTime frame: 6 weeks
  2. Change in hemoglobin comparing one dose Ferric bepectate and two dose Ferinject treatmentTime frame: 6 weeks
  3. Incidence of treatment emergent adverse eventsTime frame: 2 hours post infusion start

Locations

24 sites in 5 countries. Site status is shown where the registry gives one.

  • Trialmed Phoenix

    Phoenix, Arizona · Recruiting

  • PharmaSouth Research

    Coral Gables, Florida · Recruiting

  • M3 Wake Research - Lake City

    Lake City, Florida · Recruiting

  • Trialmed Melbourne

    Melbourne, Florida · Recruiting

  • Trialmed The Villages

    The Villages, Florida · Recruiting

  • Trialmed Evansville

    Evansville, Indiana · Recruiting

  • Ingham Nephrology & Hypertension, P.C.

    Lansing, Michigan · Recruiting

  • Brookhaven Heart

    Patchogue, New York · Recruiting

  • Trialmed Asheboro

    Asheboro, North Carolina · Recruiting

  • M3 Wake Research - Raleigh

    Raleigh, North Carolina · Recruiting

  • M3 Wake Research - Charleston

    Charleston, South Carolina · Recruiting

  • Trialmed Austin

    Austin, Texas · Recruiting

  • M3 Wake Research

    Dallas, Texas · Recruiting

  • PatientCare Clinical Research

    Houston, Texas · Recruiting

  • Trialmed San Antonio

    San Antonio, Texas · Recruiting

  • Medical Center Levitas EOOD

    Sofia, Bulgaria · Not yet recruiting

  • Momentum West Auckland

    Auckland, New Zealand · Not yet recruiting

  • Momentum Waikato

    Hamilton, New Zealand · Not yet recruiting

  • Momentum Hutt Valley

    Upper Hutt, New Zealand · Not yet recruiting

  • Szpital AidPort

    Skórzewo, Poland · Not yet recruiting

  • Ames Medical Research

    Bragadiru, Romania · Not yet recruiting

  • Colentina Clinical Hospital

    Bucharest, Romania · Not yet recruiting

  • Sana Medical Center

    Bucharest, Romania · Not yet recruiting

  • The Oncology Institute

    Cluj-Napoca, Romania · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.